Elsevier

Life Sciences

Volume 61, Issue 22, 24 October 1997, Pages 2157-2165
Life Sciences

Prevention of hypoxemia-induced renal dysfunction by perindoprilat in the rabbit

https://doi.org/10.1016/S0024-3205(97)00918-1Get rights and content

Abstract

The role of angiotensin II, a potent postglomerular vasoconstrictor, in the hypoxemiainduced renal changes is still controversial. The ability of perindoprilat, an angiotensin converting-enzyme inhibitor, to prevent the acute renal effects of hypoxemia was assessed in 22 anesthetized-ventilated rabbits. In 8 untreated rabbits, hypoxemia induced a significant drop in mean blood pressure (MBP) (−12 ± 2%), glomerular filtration rate (GFR) (−16 ± 3%) and renal blood flow (RBF) (−12 ± 3%) with a concomittant increase in renal vascular resistance (RVR) (+18 ± 5%) and urine flow rate (+33 ± 14%), and without any changes in filtration fraction (FF) (−4 ± 2%). This suggests the occurrence of glomerular vasoconstriction during the hypoxemic stress. In 7 normoxemic rabbits, intravenous perindoprilat (20 μgkg) induced an increase in urine flow rate (+17 ± 4%) and RBF (+17 ± 4%), and a decrease in MBP (−6 ± 1%), RVR (−14 ± 3%) and FF (−11 ± 2%) without a significant change in GFR. The drop in FF and the increase in RBF suggests preferential postglomerular vasodilatation. In 7 rabbits, perindoprilat prevented the occurence of the hypoxemia-induced changes in RBF and RVR without improving MBP. FF decreased significantly (−18 ± 2%), while the drop in GFR (−7 ± 2%) was partially blunted and the increase in urine flow rate (+25 ± 9%) was confirmed. These results could be explained by the inhibition of the angiotensin-mediated efferent vasoconstriction and by the inhibition of bradykinin degradation by perindoprilat. These data confirm the ability of converting-enzyme inhibitors to prevent the renal hypoperfusion induced by acute hypoxemia.

References (45)

  • J.-B. Gouyon et al.

    Kidney Int.

    (1988)
  • A.C. Bratton et al.

    J. Biol. Chem.

    (1939)
  • B.H. Clappison et al.

    Kidney Int.

    (1981)
  • M.S. Dietrich et al.

    Microvasc. Res.

    (1991)
  • L. Ballevre et al.

    Pediatr. Res.

    (1996)
  • D. Semama et al.

    Biol. Neonate

    (1995)
  • R.C. Blantz et al.

    Kidney Int.

    (1987)
  • H.R. Brunner et al.

    Kidney Int.

    (1987)
  • J.E. Hall
  • C.G. Navar et al.
  • L. Rosivall et al.

    Am. J. Physiol.

    (1983)
  • R.E. Tuffley et al.

    J. Endoc.

    (1970)
  • F. Broughton-Pipkin et al.

    J. Pediatr.

    (1977)
  • D.N. Weissmann et al.

    Life Sci.

    (1981)
  • D. Davidson et al.

    J. Clin. Invest.

    (1984)
  • H. Raff et al.

    Am. J. Physiol.

    (1988)
  • J.-P. Guignard et al.

    Kidney Int.

    (1981)
  • R.J. Macfayden et al.

    Drugs

    (1990)
  • J. Nussberger et al.

    J. Cardiovasc. Pharmacol.

    (1987)
  • H.K. Wright et al.

    J. Lab. Clin. Med.

    (1966)
  • P.H. Wiesel et al.

    J. Pharmacol. Exp. Ther.

    (1990)
  • B.R. Walker

    Am. J. Physiol.

    (1982)
  • Cited by (13)

    View all citing articles on Scopus
    View full text